Shopping Cart
- Remove All
- Your shopping cart is currently empty
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 1.9 nM and a reporter gene IC50 of 6.1 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $3,170 | 10-14 weeks | |
50 mg | $4,180 | 10-14 weeks | |
100 mg | $5,800 | 10-14 weeks |
Description | TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 1.9 nM and a reporter gene IC50 of 6.1 nM. |
Targets&IC50 | RORγt, binding IC50:1.9 nM , RORγt, reporter gene IC50:6.1 nM |
In vivo | In mice with IL-23-induced cytokine expression model, TAK-828F (0.3, 1, and 3 mg/kg; orally administered; b.i.d.; 28 days; ) shows robust and dose-dependent inhibition of IL-17A expression with an ED80 of 0.5 mg/kg. |
Molecular Weight | 509.57 |
Formula | C28H32FN3O5 |
Cas No. | 1854901-94-2 |
Relative Density. | 1.322 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.